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Dear Editor,
Arsenic trioxide (As2O3) is a standard medication for
relapsed acute promyelocytic leukemia (APL). However,
high blood arsenic levels lead to potentially fatal arrhyth-
mias. As2O3 is renal-excreted and considered contraindi-
cated in renal failure.
A 42-year-old man was referred for treatment of APL in
first relapse, presenting with pancytopenia, impaired renal
function, and septicemia. He was treated with all-trans ret-
inoic acid (ATRA, 45 mg/m2/day) and oral As2O3 (10 mg/
day) [1]. Progressive renal function derangement developed,
necessitating reduction of oral As2O3 to 5 mg/day. On the
third day, the leukocyte count increased to 8.9×109/L, asso-
ciated with bilateral pulmonary infiltrates. Features were
consistent with the APL differentiation syndrome, which
with the underlying septicemia led to anuric acute renal
failure. ATRA was stopped. Idarubicin (6 mg/m2/day×5),
dexamethasone (12 mg/day×7), and alternate daily hemo-
dialysis were administered. Oral As2O3 at 5 mg was given
after each hemodialysis and was stopped after 9 days. At
4 weeks, marrow examination confirmed complete remission.
He remained anuric, and hemodialysis was continued. Oral
As2O3 was re-commenced at 2 mg after each hemodialysis.
Two months later, continuous ambulatory peritoneal dialysis
(CAPD) was started. A maintenance regimen for APL, com-
prising oral As2O3 (5 mg/day) and ATRA (20 mg twice daily)
[2, 3], given 2 weeks every 2 months, was administered. At 6-
month follow-up, he remained in remission and was negative
for the PML-RARA fusion gene characteristic of APL. No
cardiac arrhythmias were observed at any time.
Serum elemental arsenic levels were assayed by inductively
coupled plasma mass spectrometry [3, 4], on blood samples
sent for creatinine measurement. At 4 days, there was a sudden
increase of arsenic levels, as the cellular and third-space com-
partments became saturated and anuria prevented arsenic excre-
tion (Fig. 1a). The arsenic level peaked at 4,240 nmol/L, outside
the therapeutic range of 500–2,000 nmol/L typical of oral
As2O3. The commencement of hemodialysis and cessation of
oral As2O3 resulted in a fall of arsenic levels parallel to those of
creatinine. After oral As2O3 was re-commenced, arsenic levels
gradually increased to the therapeutic range (Fig. 1b). As
arsenic clearance in oral As2O3 therapy during CAPD had been
documented previously [3], arsenic assays were not performed
after peritoneal dialysis was started.
As2O3 is a key medication for patients with relapsed APL.
Intravenous (i.v.) As2O3, used in most reports, may lead to
lethal arrhythmias due to QT prolongation, which is directly
proportional to blood arsenic levels [5]. Because i.v. As2O3
leads to a rapid surge of blood arsenic levels, arrhythmia
related to QT prolongation is an important adverse effect. Oral
As2O3 is slowly absorbed and results in lower blood arsenic
levels. Its bioavailability, estimated by area-under-the-curve
pharmacokinetically, is comparable to that of i.v. As2O3 [6].
Hence, oral As2O3 has the same efficacy, but little risk of
arrhythmia [5]. In one previous report, blood arsenic levels
after i.v. As2O3 were measured in an APL patient on hemo-
dialysis [7]. The peak level was 6,450 nmol/L, a toxic level
that led to termination of i.v. As2O3 therapy. It was concluded
that i.v. As2O3 was contraindicated in renal failure [7]. In our
case, the sudden increase in blood arsenic levels was related to
an unanticipated acute renal failure. Timely cessation of oral
As2O3 and institution of hemodialysis prevented further
increases in arsenic levels. Subsequently, with careful dose
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adjustment and meticulous monitoring, oral As2O3 was safely
administered during hemodialysis. The blood arsenic levels
were also kept within the therapeutic range. We have also
previously demonstrated the safety of oral As2O3 during
CAPD. Therefore, patients on renal replacement therapy are
still eligible for oral As2O3 treatment.
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Fig. 1 a Blood arsenic levels
during the first 3 weeks of
hemodialysis. A rapid surge of
arsenic levels occurred on day 5,
in parallel with a rise in creatinine
and further renal function
deterioration. Oral arsenic
trioxide was stopped on day 9,
resulting in a gradual fall of
arsenic levels after hemodialysis
was commenced. Days (sample
number): 3 (1–4), 4 (5–7), 5 (8), 6
(9), 7 (10–13), 8 (14–16), 9 (17–
19), 10 (20–21), 11 (22), 12 (23),
13 (24), 14 (24–26), 15 (28–30),
16 (31–32), 17 (33–34), 18 (35–
36), 19 (37–38), 20 (39), 21 (40),
22 (41), 23 (42), and 24 (43). b
Blood arsenic levels during the
second month of hemodialysis.
With the re-commencement of
oral arsenic trioxide on day 42,
there was a gradual increase of
arsenic levels back to the thera-
peutic range. Arsenic levels also
varied in parallel with creatinine
levels during hemodialysis and
had remained within the thera-
peutic range
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